Overview > The ELMA Foundation > AIDS-Free
Focus Area:
AIDS-Free
We succeed when the number of new HIV infections in children is reduced, and when countries are on track to eliminate pediatric AIDS by 2030.
Current Investments
Project support for involvement in ELMA’s Unfinished Business Phase II to scale effective pediatric and adolescent HIV case finding and ART linkage strategies, improve treatment models, and build an investment case for national adoption
Project support to strengthen pediatric and adolescent HIV service delivery through technical support in high-burden countries, coordination of global tools and best practices, and accelerated access to pediatric formulations of anti-retroviral therapies
Project support to coordinate Unfinished Business initiative to scale effective pediatric and adolescent HIV case finding, ART linkage strategies, improve care and treatment models, and lead development of an investment case for national scale
Project support to scale effective pediatric and adolescent HIV case finding and ART linkage strategies, improve care and treatment models, and build an investment case for national scale
General support to an organization that strengthens pediatric and adolescent HIV service delivery by providing technical support and accelerated access to optimal pediatric formulations in high-burden countries
Project support for the management of the WHO's Global Accelerator for Pediatric Formulations (GAP-f) network, which aims to accelerate access to safe, effective, quality, affordable pediatric medicines
Project support to scale effective pediatric and adolescent HIV and TB case finding and ART linkage strategies, improve care and treatment models, and build an investment case for national scale
Project support to expand Zvandiri (a peer-led comprehensive service delivery model that supports children, adolescents, and young people living with HIV) to five countries, while adapting the model to include virtual training and mentorship that allows for effective scale-up during COVID-19 and beyond